Cargando…

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model

Peroxisome proliferator-activated receptor α/δ (PPAR α/δ), regulating glucolipid metabolism and immune inflammation, has been identified as an effective therapeutic target in non-alcoholic steatohepatitis (NASH). Dual PPAR α/δ agonist, such as GFT505 (also known as elafibranor), demonstrated potenti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Linfu, Liu, Chuang, Zhao, Manyu, Zhang, Qianru, Lu, Ying, Liu, Ping, Yang, Hua, Yang, Jinliang, Chen, Xiaoxin, Yao, Yuqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7743980/ https://www.ncbi.nlm.nih.gov/pubmed/33326461 http://dx.doi.org/10.1371/journal.pone.0243911

Ejemplares similares

Effects of the New Dual PPARα/δ Agonist GFT505 on Lipid and Glucose Homeostasis in Abdominally Obese Patients With Combined Dyslipidemia or Impaired Glucose Metabolism
por: Cariou, Bertrand, et al.
Publicado: (2011)

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
por: Cariou, Bertrand, et al.
Publicado: (2013)

Comparative RNA-sequencing profiled the differential gene expression of liver in response to acetyl-CoA carboxylase inhibitor GS-0976 in a mouse model of NASH
por: Lu, Ying, et al.
Publicado: (2019)

One Week of CDAHFD Induces Steatohepatitis and Mitochondrial Dysfunction with Oxidative Stress in Liver
por: Sugasawa, Takehito, et al.
Publicado: (2021)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase
por: Chen, Xiaoxin, et al.
Publicado: (2023)

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
por: Jain, Mukul R., et al.
Publicado: (2017)

Inhibition of Doxorubicin-Induced Senescence by PPARδ Activation Agonists in Cardiac Muscle Cells: Cooperation between PPARδ and Bcl6
por: Altieri, Paola, et al.
Publicado: (2012)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
por: Sandoval‐Rodriguez, Ana, et al.
Publicado: (2020)

Review article: vascular effects of PPARs in the context of NASH
por: Guixé‐Muntet, Sergi, et al.
Publicado: (2022)

PPAR-δ agonist affects adipo-chondrogenic differentiation of human mesenchymal stem cells through the expression of PPAR-γ
por: Kim, Dong Hyun, et al.
Publicado: (2020)

Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor
por: Kamata, Shotaro, et al.
Publicado: (2023)

Osteopontin-Targeted and PPARδ-Agonist-Loaded Nanoparticles Efficiently Reduce Atherosclerosis in Apolipoprotein E(–/–) Mice
por: Huang, Xu, et al.
Publicado: (2022)

NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis?
por: Mackenzie, Gerardo G., et al.
Publicado: (2008)

Sanguisorba officinalis L. Ameliorates Hepatic Steatosis and Fibrosis by Modulating Oxidative Stress, Fatty Acid Oxidation, and Gut Microbiota in CDAHFD-Induced Mice
por: Nam, Yunseong, et al.
Publicado: (2023)

Identification of novel multitargeted PPARα/γ/δ pan agonists by core hopping of rosiglitazone
por: Wang, Xue-Jiao, et al.
Publicado: (2014)

Effects of the PPAR-β/δ agonist GW0742 during resuscitated porcine septic shock
por: Wepler, Martin, et al.
Publicado: (2013)

505 Verdades publicitarias /
por: Pratt Gaballí, Pedro
Publicado: (2001)

PPARα agonist and metformin co-treatment ameliorates NASH in mice induced by a choline-deficient, amino acid-defined diet with 45% fat
por: Okishio, Shinya, et al.
Publicado: (2020)

PPAR-δ in Vascular Pathophysiology
por: Wang, Nanping
Publicado: (2008)

Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy
por: Yao, Yuqin, et al.
Publicado: (2020)

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
por: Boeckmans, Joost, et al.
Publicado: (2019)

PPARδ repression in Huntington’s disease and its essential role in CNS translate into a potent agonist therapy
por: Dickey, Audrey S., et al.
Publicado: (2015)

A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice
por: Chen, Wei, et al.
Publicado: (2015)

PPARδ Agonist Promotes Type II Cartilage Formation in a Rabbit Osteochondral Defect Model
por: Song, Ju-Yong, et al.
Publicado: (2022)

Safety of PPAR Agonists
por: Home, Philip
Publicado: (2011)

PPARγ and PPARδ as Modulators of Neoplasia and Cell Fate
por: Glazer, Robert I., et al.
Publicado: (2008)

Conditional Expression of Human PPARδ and a Dominant Negative Variant of hPPARδ In Vivo
por: Higgins, Larry G., et al.
Publicado: (2012)

The Effect of PPARα, PPARδ, PPARγ, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice
por: Harrington, W. Wallace, et al.
Publicado: (2007)

Investigating the Role of PPARβ/δ in Retinal Vascular Remodeling Using Pparβ/δ-Deficient Mice
por: Ho, Sze Yuan, et al.
Publicado: (2020)

PPARδ Activation Protects Endothelial Function in Diabetic Mice
por: Tian, Xiao Yu, et al.
Publicado: (2012)

The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state
por: Adhikary, Till, et al.
Publicado: (2015)

PPARδ, a Potential Therapeutic Target for Heart Disease
por: Yang, Qinglin, et al.
Publicado: (2018)

PPARδ Agonist GW501516 Inhibits PDGF-Stimulated Pulmonary Arterial Smooth Muscle Cell Function Related to Pathological Vascular Remodeling
por: Liu, Guangjie, et al.
Publicado: (2013)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

SUN-505 The Invincible Parathyroid Gland
por: Mayorga, Mabel, et al.
Publicado: (2019)

Administration of PPARβ/δ agonist reduces copper-induced liver damage in mice: possible implications in clinical practice
por: Sanchez-Siles, Alvaro A., et al.
Publicado: (2011)

Inverse PPARβ/δ agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion
por: Adhikary, T, et al.
Publicado: (2013)

PPARβ/δ Agonist Alleviates Diabetic Osteoporosis via Regulating M1/M2 Macrophage Polarization
por: Chen, Miao, et al.
Publicado: (2021)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rc58ram6q9bbl7i7hd2lqndc08